Literature DB >> 12975226

Diagnosis and management of hyperprolactinemia.

Omar Serri1, Constance L Chik, Ehud Ur, Shereen Ezzat.   

Abstract

Prolactin is a pituitary hormone that plays a pivotal role in a variety of reproductive functions. Hyperprolactinemia is a common condition that can result from a number of causes, including medication use and hypothyroidism as well as pituitary disorders. Depending on the cause and consequences of the hyperprolactinemia, selected patients require treatment. The underlying cause, sex, age and reproductive status must be considered. We describe the diagnostic approach and management of hyperprolactinemia in various clinical settings, with emphasis on newer diagnostic strategies and the role of various therapeutic options, including treatment with selective dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975226      PMCID: PMC191295     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  18 in total

1.  Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.

Authors:  C Di Somma; A Colao; A Di Sarno; M Klain; M L Landi; G Facciolli; R Pivonello; N Panza; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

2.  The natural history of untreated hyperprolactinemia: a prospective analysis.

Authors:  J Schlechte; K Dolan; B Sherman; F Chapler; A Luciano
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

3.  Management of prolactinomas during pregnancy.

Authors:  M E Molitch
Journal:  J Reprod Med       Date:  1999-12       Impact factor: 0.142

4.  Relapse of hyperprolactinemia revisited.

Authors:  O Serri; J Hardy; F Massoud
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

5.  A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.

Authors:  D A De Luis; A Becerra; M Lahera; J I Botella; C Varela
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.

Authors:  A Di Sarno; M L Landi; P Cappabianca; F Di Salle; F W Rossi; R Pivonello; C Di Somma; A Faggiano; G Lombardi; A Colao
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

7.  Long-term follow-up of patients with hyperprolactinaemia.

Authors:  W J Jeffcoate; N Pound; N D Sturrock; J Lambourne
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

8.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

9.  Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.

Authors:  B M Biller; H B Baum; D I Rosenthal; V C Saxe; P M Charpie; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings.

Authors:  E Thodou; S L Asa; G Kontogeorgos; K Kovacs; E Horvath; S Ezzat
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  41 in total

1.  More about hyperprolactinemia.

Authors:  Malvinder S Parmar
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

2.  More about hyperprolactinemia.

Authors:  Christopher S Kovacs
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

3.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

4.  Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.

Authors:  Sophie Vallette; Karim Serri; Juan Rivera; Patricia Santagata; Sophie Delorme; Natasha Garfield; Nora Kahtani; Hugues Beauregard; Nahla Aris-Jilwan; Ghislaine Houde; Omar Serri
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS.

Authors:  Silvia S Rodriguez; Maria G Castro; Oscar A Brown; Rodolfo G Goya; Gloria M Console
Journal:  Expert Rev Endocrinol Metab       Date:  2009-07-01

6.  Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.

Authors:  Istvan Bitter; Jeffrey A Lieberman; Florence Gaudoux; Pierre Sokoloff; Mélanie Groc; Rajeev Chavda; Cécile Delsol; Laurence Barthe; Valérie Brunner; Carine Fabre; Marine Fagard; Agnès Montagne; Françoise Tonner
Journal:  Neuropsychopharmacology       Date:  2019-03-01       Impact factor: 7.853

Review 7.  A 68-year-old man with an incidentally discovered pituitary lesion.

Authors:  Omar Saeed; Manoela Braga
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

8.  Polycystic ovary syndrome: validated questionnaire for use in diagnosis.

Authors:  Sue D Pedersen; Sony Brar; Peter Faris; Bernard Corenblum
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

9.  Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.

Authors:  Crésio Alves; Ana Cláudia Alves
Journal:  Childs Nerv Syst       Date:  2008-08-09       Impact factor: 1.475

10.  The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.

Authors:  Maria Stella Calafato; Isabelle Austin-Zimmerman; Johan H Thygesen; Mani Sairam; Antonio Metastasio; Louise Marston; Francisco Abad-Santos; Anjali Bhat; Jasmine Harju-Seppänen; Haritz Irizar; Eirini Zartaloudi; Elvira Bramon
Journal:  Pharmacogenomics J       Date:  2020-02-04       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.